Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 10/28/21
Akebia Therapeutics to Report Third Quarter 2021 Financial Results and Highlight Recent Company MilestonesPRNewsWire • 10/26/21
Akebia Announces Vadadustat Efficacy and Safety Data to be Presented at American Society of Nephrology Kidney Week 2021PRNewsWire • 10/18/21
Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/05/21
Akebia Therapeutics (AKBA) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/05/21
Akebia Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company MilestonesPRNewsWire • 08/05/21
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akebia Therapeutics, Inc. and Encourages Investors who Formerly Held Shares of Keryx Biopharmaceuticals (KERX) to Contact the FirmBusiness Wire • 07/27/21
SHAREHOLDER ALERT: Robbins LLP Announces that Akebia Therapeutics, Inc. (AKBA) is Being Sued for Misleading Keryx Biopharmaceuticals, Inc. (KERX) Shareholders Ahead of MergerBusiness Wire • 07/26/21
Akebia Therapeutics to Report Second Quarter 2021 Financial Results and Discuss Recent Business HighlightsPRNewsWire • 07/26/21
Akebia Therapeutics Stock Jumps as FDA Accepts Vadadustat US Application in CKD-Related AnemiaBenzinga • 06/01/21
Akebia and Otsuka Announce FDA Acceptance for Filing of New Drug Application for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on DialysisPRNewsWire • 06/01/21
Implied Volatility Surging for Akebia Therapeutics (AKBA) Stock OptionsZacks Investment Research • 05/25/21
Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/10/21
Akebia Reports First Quarter 2021 Financial Results and Highlights Recent Company MilestonesPRNewsWire • 05/10/21